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Purpose: To evaluate circulating irisin levels in patients with active and controlled Cushing’s
disease (CD).
Design: Forty-four patients with CD evaluated during the active phase and after 12 months
of biochemical remission and 40 controls were recruited.
Methods: Phenotypic, anthropometric, hormonal and metabolic parameters, including insu-
lin sensitivity estimation by homeostatic model of insulin resistance, Matsuda index and oral
disposition index and circulating irisin levels were evaluated.
Results: Patients with active CD showed lower irisin levels compared to controls (p<0.001) and
controlled CD (p<0.001). The independent variables significantly associated with irisin were
waist circumference (WC) (p=0.025), body fat percentage (BF%) (p=0.009), PTH (p=0.007) and
chair rising test (CRT) (p<0.001) in active CD and WC (p=0.013), BF% (p=0.014), PTH
(p=0.038), CRT (p=0.029) and urinary-free cortisol (p<0.001) in controlled CD.
Conclusion: Circulating irisin levels tend to be lower in patients with active CD compared
to those with controlled CD and controls. They are strongly associated with osteosarcopenia
and central obesity in CD and therefore may be a possible marker of diagnosis.
Keywords: irisin, osteoporosis, myopathy, Cushing’s disease
Introduction
Irisin is a molecule secreted from skeletal muscle and induced by over-expression
of the peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-
1α).1 It is produced as a result of cleavage of the membrane protein fibronectin type
III domain-containing protein 5 (FNDC5) and contributes to maintenance of meta-
bolic homeostasis via induction of “browning” of white adipocytes through
increased expression of uncoupling protein 1 (UCP1), leading to increased energy
expenditure2,3 and reducing the risk of obesity and diabetes.2,4
Some studies report the role of FNDC5/irisin in several diseases, such as diabetes,
hypothyroidism, atherosclerosis, non-alcoholic fatty liver disease, GHD, osteoporosis,
obesity and acromegaly.5–11 Serum irisin levels are closely related to metabolic diseases
and activation of FNDC5 showed beneficial clinical effects in animals and humans.12 In
an animal study, FNDC5 knockout mice showed severe hepatic steatosis with impaired
autophagy and fatty acid oxidation. In contrast, FNDC5 over-expression prevented
hyperlipidaemia, hepatic lipid accumulation and autophagy impairment in the high-fat
diet mouse.13
Cushing’s disease (CD) is caused by prolonged exposure to inappropriately high
levels of cortisol as a consequence of a pituitary ACTH-secreting tumour. It is associated
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with an increased mortality rate compared to the general
population mainly due to the metabolic, cardiovascular, psy-
chiatric and musculoskeletal comorbidities associated with
hypercortisolism.14–17 Skeletal muscle is strongly influenced
by glucocorticoid levels, resulting in muscle atrophy and
weakness in patients with CD. Muscle weakness has been
reported in 40–70% of patients with Cushing’s syndrome
(CS)18–20 commonly affecting the proximal musculature of
the lower limbs. Accordingly, patients typically complain
about inability to get up from a squatting position or to climb
stairs whereas running or walking is less frequently affected.21
However, in patients with CD, the presence of sarcopenia is
generally associated with obesity and osteoporosis, leading to
a condition called osteosarcopenic obesity. The pathomechan-
ism that leads to sarcopenic obesity has not yet been identified
but is probably related to low-grade inflammation and insulin
resistance. Because irisin is predominantly synthesized and
secreted from skeletal muscle, there have been several studies
investigating the association of irisin with muscle,22,23 with
inconsistent results. A recent study documented a positive
correlation of irisin and sarcopenia in postmenopausal
women,24 showing a potential for the development of irisin-
based early screening and of a staging tool for sarcopenia.
A relationship between irisin and bone has also been
demonstrated.25 Due to the wide effects of irisin on skeletal
muscle, bone, adipose tissue and glucose metabolism, which
are targets of cortisol action, changes in irisin levels may be
correlated with cortisol excess.
The aim of the study was to evaluate circulating irisin
levels in patients with CD before and after remission and
to clarify whether circulating levels of irisin are positively
associated with phenotypic, cardiovascular and metabolic
parameters in CD.
Patients and Methods
Subjects and Study Design
A total of 44 patients with active CD, referred to the Division
of Endocrinology of Palermo University from January 2013
to December 2018, 35 of them women (80%) and 9 men
(20%) (mean age 48.5 ± 15 years; mean duration of disease
34.02 ± 22.3 years) were included in this observational real-
life study. The diagnosis of CDwas based on clinical features
and laboratory assessments according to the clinical practice
guidelines and a consensus statement.26,27
The control group was recruited in parallel between
2013 and 2018 and consisted of 40 patients, 33 of them
women (82.5%) and 7 men (17.5%) (mean age 48.2 ± 13.2
years) referred with a suspicion of CS, subsequently ruled
out by repeated biochemical assessments. Controls were
matched for age and gender.
Clinical signs such as moon face, facial rubor, dorsal fat
pad or buffalo hump, purple striae and myopathy were eval-
uated for active and controlled CD and controls. Fatty tissue
deposits, particularly around themidsection and upper back, in
the face and between the shoulders, were defined moon face
and buffalo hump, respectively. Purple striae were defined as
wide, reddish-purple streaks.Myopathywas defined asmuscle
weakness at the proximal level with the pelvic girdle muscle
involved. In order better to evaluate muscle performance, the
chair rising test was performed as previously described.28,29
Patientswere instructed to rise froma sitting position on a chair
45 cm high as fast as possible. They kept their arms crossed
over their chests while performing the chair rising test and rose
until reaching full knee and hip extension. The seconds needed
to execute this procedure were recorded, with higher numbers
indicating more severe muscle impairment.
Cardiovascular, metabolic and bone comorbidities, such
as visceral obesity, impaired fasting glucose (IFG) and
impaired glucose tolerance (IGT), diabetes mellitus, meta-
bolic syndrome, hypertension, hypercholesterolemia, hepa-
tic steatosis and osteoporosis/osteopaenia were also
evaluated in both active and controlled CD and in controls.
The metabolic syndrome was diagnosed according to the
NCEP ATP III criteria, whereas diabetes mellitus and pre-
diabetes were diagnosed according to the ADA criteria.30,31
For patients with a previous diagnosis of diabetes (14
out of 44), hypoglycaemic agents were discontinued 24
h before metabolic evaluations, to avoid any interference
with metabolic parameters. Among patients with diabetes,
11 were on treatment with metformin, while 2 were on
combined metformin and sulphonylurea and 1 other with
metformin and DPP-4 inhibitors. All of them were on
good metabolic control (HbA1c ≤ 53 mmol/mol).
Patients were not taking vitamin D supplementation.
In the active phase and after remission of CD and for
controls, clinical parameters such as BMI and WC, mea-
sured at the midpoint between the lower rib and the iliac
crest, were assessed. Body fat percentage (BF%) was
calculated by prediction formula [BF%=1.20 x BMI -
10.8 x sex + 0.23 x age - 5.4 (males=1; females=0)].32
After an overnight fast, lipids [total cholesterol (TC), HDL
cholesterol, LDL cholesterol and triglycerides (TG)],
HbA1c, glycaemia, insulinaemia and circulating irisin
levels were evaluated. As hormonal parameters, we eval-
uated UFC as the mean of three 24-h urine collections
Guarnotta et al Dovepress
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(mUFC), cortisol after a low dose of dexamethasone sup-
pression test and plasma ACTH.
Insulin sensitivity was indirectly estimated using basal
insulin and glucose values to calculate the homeostatic model
of insulin resistance (HOMA2-IR) [glycaemia (mmol/l)
x insulinemia (mU/mL)/22.5].33 The Matsuda index of insu-
lin sensitivity (ISI-Matsuda) [10,000/glucose (mg/dl)
x insulin (mU/mL) x glucose mean x insulin mean],34 the
oral disposition index (DIo) [(ΔInsulin0–30/ΔGlucose0–30)
x (1/fasting insulin)]35 and the area under the curve for
insulin (AUC2h insulinemia) and glucose (AUC2h glycaemia)
were derived from an oral glucose tolerance test (OGTT)
performed in 30 patients with active CD and in 20 controls
who had no previous diagnosis of diabetes.
In 28 patients with CD, the remission resulted from trans-
sphenoidal surgery, in 12 patients from medical treatment
(carried out after unsuccessful pituitary surgery) and in 4
patients from adrenalectomy (carried out after unsuccessful
pituitary surgery and medical treatments). Corticosteroid
replacement therapy was administered after transsphenoidal
surgery starting at 25–37.5 mg cortisone acetate daily and then
tapered up to suspension (mean duration of treatment 6.37 ±
2.11 months). In patients who developed adrenal insufficiency
after adrenalectomy, cortisone acetate at the dose of 50 ±
12.5 mg/day was administered. In patients medically treated,
9 were treated with pasireotide and 3 with metyrapone.
All patients included in the study were instructed not to
practice physical activity during the 2 weeks before the
biochemical assays. To assess adherence to this instruction,
a 7-day pedometer measurement was provided to each
patient, with the instruction to take less than 5000 steps a day.
Exclusion criteria were adrenal-dependent hypercorti-
solism, pregnancy, women taking oral contraceptives and
patients who developed multiple pituitary hormonal defi-
ciency after pituitary surgery.
The study protocol was approved by the Ethics
Committee of the Policlinico Paolo Giaccone hospital, in
accordance with the Declaration of Helsinki and written
informed consent was obtained from all patients.
Assays
Insulin, glycaemia, calcium, phosphorus and lipids were
measured by standard methods (Modular P800, Roche,
Milan). LDL-C levels were measured using the
Friedewald formula [TC – (HDL + (TG/5)]. HbA1c levels
were determined by HPLC with an ion-exchange resin
(Bio-Rad Laboratories, Milan, Italy).
PTH, vitamin D, ACTH, cortisol and UFC levels were
detected by electrochemiluminescence immunoassay (ECLIA,
Elecsys, Roche, Milan) following the manufacturer’s instruc-
tions. Normal values for hormonal markers were defined as
follows: ACTH 2.2–14 pmol/L and UFC 59–378 nmol/24 h.
Serum samples were analyzed for irisin concentration
using a commercial enzyme immunoassay kit (EK-067-29;
Phoenix Pharmaceuticals, Karlsruhe, Germany). The lowest
detectable concentration of irisin was 6.8 ng/mL, and the high-
est was 19.1 ng/mL. The kit used in the current study was
validated against Western blotting and mass spectrometry.36
Samples were assayed following the manufacturer’s instruc-
tions without a prior extraction step. Serum samples used for
circulating irisin assays were collected from 2013. These sam-
ples were stored at −80°Cwithout repeated freezing and thaw-
ing for not more than 2 years before the analysis.
The conversion factors for the International System (SI)
were as follows: glucose mg/dl vs mmol/L: 0.0555; insulin
mUI/mL vs pmol/L: 6.945; TC and HDL-cholesterol mg/dl vs
mmol/L: 0.0259; triglycerides mg/dl vs mmol/L: 0.0113;
HbA1c % vs mmol/mol: 10.93% - 23.5; cortisol µg/dl vs
nmol/L: 27.59, UFC µg/24h vs nmol/24h: 2.76; ACTH pg/
mL vs pmol/L: 0.22, vitamin D ng/mL vs nmol/L: 2.49.
Statistical Analysis
The Statistical Packages for Social Science SPSS version 19
(SPSS, Inc.) was used for data analysis. The normality of
quantitative variables was tested with the Shapiro–Wilk test.
Data were presented as mean ± SD for continuous variables.
Rates and proportions were calculated for categorical vari-
ables. The differences between paired continuous variables
(active vs remission CD and active CD vs controls) were
analyzed using one-way ANOVA. Relations between the
outcome variables and continuous variables were evaluated
using univariate Pearson correlation coefficients. Multiple
linear regression analysis was performed to identify inde-
pendent predictors of the dependent variable irisin in active
and controlled CD. The decision to keep the variables in the
multivariate model was based on clinical and statistical
significance. Variables having a potential clinical impact on
irisin levels and significantly associated with irisin on uni-
variate analysis (Pearson correlation) were included.
A p-value of 0.05 was considered statistically significant.
Results
Patients with active CD showed higher percentages of myo-
pathy (p<0.001), facial rubor (p=0.016), buffalo hump
(p=0.002), hypertension (p=0.033), hypercholesterolemia
Dovepress Guarnotta et al
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(p=0.016) and osteoporosis/osteopaenia (p=0.014) than con-
trols (Table 1). In addition, patients with active CD had
higher percentages of moon face (p<0.001), myopathy
(p=0.003), facial plethora (p<0.001), buffalo hump
(p<0.001), purple striae (p=0.001), hypertension (p=0.032),
hypercholesterolemia (p=0.001), metabolic syndrome
(p=0.001), central obesity (p<0.001) and osteoporosis/osteo-
paenia (p=0.002) than those with remission (Table 1).
Regarding anthropometric, metabolic and hormonal
parameters, patients with active CD had higher BMI
(p=0.001), WC (p=0.038), BF% (p=0.008), ACTH
(p<0.001), mUFC (p=0.009), cortisol after low doses of
dexamethasone suppression test (p=0.011), HbA1c
(p=0.028), TC (p<0.001), LDL-cholesterol (p=0.016),
PTH (p=0.005) and CRT (p<0.001) and lower vitamin
D (p=0.018) and irisin (p<0.001) than controls (Table 2).
On the other side, patients with controlled CD showed
lower BMI (p<0.001), WC (p<0.001), ACTH (p<0.001),
mUFC (p<0.001), cortisol after low dose of dexametha-
sone suppression test (p<0.001), glycaemia (p=0.025),
insulin (p=0.001), HOMA-IR (p=0.039), ISI-Matsuda
(p=0.024), AUC 2hinsulinemia (p=0.003), TC (p<0.001), TG
(p=0.017), LDL-cholesterol (p=0.034), PTH (p=0.002),
GOT (p=0.037), GPT (p=0.001), CRT (p<0.001) and
higher vitamin D (p=0.042) and irisin levels compared to
those with active CD (Table 2).
In patients with active CD, irisin was inversely correlated
with central obesity (r=−0.485; p=0.003), myopathy (r=0.388,
p=0.019), BMI (r=−0.363, p=0.002), WC (r=−0.346,
p=0.039), BF% (r=−0.298, p=0.003), PTH (r=−0.419,
p=0.007), CRT (r=−0.833, p<0.001). In patients with con-
trolled CD irisin was inversely correlated with central obesity
(r=−0.771, p< 0.001), myopathy (r=0.379, p=0.021), BMI
(p=−0.811, p=0.041), WC (p=−0.395, p=0.017), BF% (r=
−0.282, p=0.014), mUFC (r=−0.797, p<0.001), cortisol after
low dose of dexametasone suppression test (r=−0.337,
p=0.045), PTH (r=−0.329, p=0.038) and CRT (r=−0.618, p<
0.001) (Table 3). No other significant correlationswith clinical,
phenotypic, hormonal and biochemical parameters were found
(data not shown).
Multivariate analysis showed that WC (p=0.025), BF%
(p=0.009), PTH (p=0.007) and CRT (p<0.001) were inde-
pendently associated with irisin in patients with active CD
(Figure 1). In patients with controlled CD, the multivariate
analysis showed that WC (p=0.013), BF% (p=0.014), PTH
(p=0.038), CRT (p=0.029) and mUFC (p<0.001) were
independently associated with irisin (Figure 2).
Discussion
This study shows that patients with CD have lower irisin
values than controls and that remission of hypercortisolism
is able to increase these values, even though patients with
Table 1 Phenotypic Parameters and Comorbidities of Patients with Active and Controlled Cushing’s Disease and Controls
Controls
(N=40)
Patients with Active CD
(N=44)
Patients with Controlled CD
(N=44)
pa pb
Subjects (%) Subjects (%) Subjects (%)
Moon face 24 (60%) 30 (68.1%) 0 0.441 <0.001
Myopathy 10 (25%) 33 (75%) 7 (17.5%) <0.001 0.003
Facial rubor 9 (22.5%) 21 (47.7%) 0 0.016 <0.001
Buffalo hump 11 (27.5%) 30 (68.1%) 0 0.002 <0.001
Purple striae 14 (35%) 9 (20.4%) 0 0.136 0.001
Hypertension 18 (45%) 30 (68.1%) 20 (45.4%) 0.033 0.032
Hypercholesterolemia 14 (35%) 27 (61.3%) 11 (25%) 0.016 0.001
Metabolic syndrome 19 (47.5%) 27 (61.3%) 12 (27.2%) 0.207 0.001
Visceral obesity 40 (100%) 42 (95.4%) 21 (47.7%) 0.172 <0.001
Osteoporosis/
Osteopenia
8 (20%) 20 (45.4%) 7 (15.9%) 0.014 0.002
Hepatic steatosis 6 (15%) 12 (27.2%) 6 (13.6%) 0.175 0.114
Diabetes mellitus 11 (27.5%) 20 (45.4%) 12 (27.2%) 0.091 0.247
IFG 6 (15%) 6 (13.6%) 2 (4.5%) 0.855 0.138
IGT 2 (5%) 6 (13.6%) 2 (4.5%) 0.182 0.138
IFG+IGT 0 2 (4.5%) 0 0.177 0.317
Notes: aDifference between control subjects and patients with active Cushing’s disease. bDifference between patients with active and controlled Cushing’s disease.
Abbreviations: IFG, impaired fasting glucose; IGT, impaired glucose tolerance; CD, Cushing’s disease.
Guarnotta et al Dovepress
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CD do not reach similar values to those of controls.
Interestingly, circulating irisin levels are associated with
the presence of myopathy, CRT, mUFC, PTH and WC in
patients with controlled CD.
To the best of our knowledge, no other studies have
evaluated circulating irisin levels in patients with CD, till
now. Irisin has been reported to be related to the amount of
muscular mass and insulin sensitivity, being considered
a protective factor against diabetes and obesity.37,38 In
the current study, we found lower irisin levels in patients
with active CD compared to control subjects and con-
trolled CD, showing that hypercortisolism and related
comorbidities induce a decrease of circulating irisin levels
than control subjects. On the other hand, remission of
hypercortisolism is able to increase circulating irisin
values, which are also associated with WC, PTH and
myopathy, even though they remain lower than in control
subjects. At multivariate analysis, we documented
Table 2 Anthropometric, Metabolic and Hormonal Values of Patients with Active and Controlled Cushing’s Disease and Controls
Controls (N=40) Patients with Active
CD (N=44)
Patients with
Controlled CD(N=44)
pa pb
Mean ± SD Mean ± SD Mean ± SD
BMI (kg/m2) 28.4 ± 5.22 33.9 ± 7.3 30.3 ± 7.05 0.001 <0.001
Waist circumference (cm) 105.4 ± 12.7 110.6 ± 8.9 102.9 ± 11.6 0.038 <0.001
BF% 38.1 ± 9.58 43.4 ± 7.9 40.3 ± 9.04 0.008 0.267
ACTH (pmol/L) 7.59 ± 2.1 15.1 ± 6.5 6.8 ± 3.4 <0.001 <0.001
Mean urinary free cortisol (nmol/24h) 306.6 ± 101.8 625.4 ± 522.7 191.5 ± 177.1 0.009 <0.001
Cortisol after low dose of dexamethasone
suppression test (nmol/L)
46.3 ± 11.8 275.9 ± 203.6 17.6 ± 10.5 0.011 <0.001
Fasting glucose (mmol/L) 5.43 ± 1.1 6.83 ± 2.22 6.03 ± 1.69 0.292 0.025
Fasting insulin (pmol/L) 91.6 ± 24 128.4 ± 57.6 57.4 ± 38.2 0.106 0.001
HbA1c (mmol/mol) 39.8 ± 0.15 51 ± 0.31 45 ± 1.32 0.028 0.057
HOMA-IR 3.07 ± 1.01 4.74 ± 2.88 1.87 ± 1.12 0.051 0.039
ISI-Matsuda 4.14 ± 1.59 3.66 ± 3.4 6.96 ± 2.9 0.345 0.024
AUC2h insulinemia 10,882 ± 2503.2 12,423.7 ± 5887.9 5087.9 ± 2470.8 0.001 0.003
AUC2h glycaemia 11,948.2 ± 3049.5 15,086.6 ± 4213.9 12,935.1 ± 1816.2 0.892 0.166
Oral disposition index (DIo) 3.7 ± 0.54 3.7 ± 2.61 4.5 ± 4.12 0.846 0.592
Total cholesterol (mmol/L) 4.51 ± 0.82 5.36 ± 1.12 4.88 ± 0.77 <0.001 <0.001
HDL cholesterol (mmol/L) 1.15 ± 0.29 1.31 ± 0.42 1.34 ± 0.36 0.092 0.769
Triglycerides (mmol/L) 1.66 ± 0.43 1.75 ± 0.69 1.51 ± 0.51 0.629 0.017
LDL cholesterol (mmol/L) 2.68 ± 0.84 3.25 ± 1.01 2.84 ± 0.74 0.016 0.034
Serum calcium (mEq/L) 9.43 ± 0.45 9.41 ± 0.63 9.34 ± 0.51 0.902 0.578
Parathyroid hormone (ng/L) 33.8 ± 8.03 53.4 ± 23.3 41.6 ± 17.8 0.005 0.002
Vitamin D (nmol/L) 66 ± 22.6 41.5 ± 18.2 52.2 ± 23.3 0.018 0.042
GOT (U/L) 22.6 ± 5.35 20.1 ± 5.02 16.8 ± 7.46 0.091 0.037
GPT (U/L) 36.2 ± 12.8 31.3 ± 18.8 20.1 ± 11.7 0.456 0.001
Chair rising test (sec) 8.19 ± 0.83 10.5 ± 1.52 8.74 ± 1.13 <0.001 <0.001
Irisin (ng/mL) 13.4 ± 2.17 4.51 ± 1.06 6.57 ± 1.59 <0.001 <0.001
Notes: aDifference between control subjects and patients with active Cushing’s disease. bDifference between patients with active and controlled Cushing’s disease.
Abbreviations: CD, Cushing’s disease, BF%, body fat percentage.
Table 3 Correlation Between Irisin and Clinical, Hormonal, and
Metabolic Parameters (Univariate Analysis) in Patients with Active and
Controlled Cushing’s Disease
Irisin
Active Cushing’s
Disease
Controlled
Cushing’s Disease
r p value r p value
Myopathy 0.388 0.019 0.379 0.021
Central obesity −0.485 0.003 −0.771 <0.001
BMI (kg/m2) −0.363 0.002 −0.811 0.041
WC (cm) −0.346 0.039 −0.395 0.017
BF% −0.298 0.003 −0.282 0.014
Urinary free cortisol (nmol/24h) −0.048 0.791 −0.797 <0.001
Cortisol after low dose of
dexamethasone suppression test
(nmol/L)
−0.045 0.805 −0.337 0.045
PTH (ng/L) −0.419 0.007 −0.329 0.038
CRT (sec) −0.833 <0.001 −0.618 <0.001
Abbreviation: CRT, chair rising test.
Dovepress Guarnotta et al
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a significant negative correlation among circulating irisin
values and WC and irisin values and BF%. The relation-
ship between irisin and body composition has been widely
evaluated, with discordant results. Some studies have
shown a positive correlation between serum irisin levels,
BMI and visceral obesity39–43 and a positive association
between irisin and fat mass, waist circumference, waist-to-
hip ratio and leptin levels, suggesting a strong correlation
with the visceral disposition of adiposity.37,42,44
Furthermore, irisin levels were significantly reduced fol-
lowing weight loss due to bariatric surgery,37 suggesting
that elevated irisin levels could be a compensatory
mechanism for the abnormal metabolism and insulin sen-
sitivity typical of obese individuals. These clinical data are
supported by the evidence that irisin stimulates browning
of white adipocytes, inhibiting adipogenesis,41 whereas
blocking irisin gene expression reduces UCP1 expression
and enhances adipogenesis in obesity.45 On the other hand,
other studies have reported a negative correlation between
irisin values and anthropometric parameters46 supporting
the view that higher serum irisin values were associated
with lower BMI and a greater reduction in body weight
likely due to stimulation of energy expenditure.47
In our study, interesting data emerged from the correla-
tion between irisin levels and mUFC. To our knowledge, this
is the first time that this correlation has been reported in
humans. Taking these aspects into account, evaluation of
circulating irisin could be of interest in patients with CD.
The relationship between irisin and cortisol has recently been
evaluated in human cell lines and mouse liver tissue.48 Kim
et al demonstrated that cortisol and corticosteroids are
involved in transcription of FNDC5, even though the variants
of the genes respond differently.48 However, no information
is currently available on exogenous cortisol treatment effects
on FNDC5 expression and additional investigations in an
in vivo setting are lacking.
The current study also documented a correlation between
irisin and CRT and presence of myopathy, suggesting that
Figure 1 Independent variables associated with circulating irisin levels in patients with active CD at multivariate analysis.
Abbreviations: WC, waist circumference; CRT, chair rising test; BF%, body fat percentage.
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circulating irisin may be a biochemical marker of sarcopenia
in patients with CD. CS is generally considered a model of
sarcopenic obesity.49 Glucocorticoids induce myopathy by
affecting proteinmetabolism via different signalling pathways.
Their main effect seems to be by induction of type 2 muscle
fibre atrophy and upregulation of protein catabolism by acti-
vating cellular proteolysis, ie, via the ubiquitin-proteasome,
the lysosomal and the calcium-dependent system.50–52
However, patients with CD suffer from myopathy more as
a severe decrease of muscle strength than as a loss of muscle
mass,49 as also widely demonstrated by the loss of grip
strength and the poor chair rising test performance.53
Decrease of muscle strength may be explained by increased
intramuscular fat infiltration and obesity may be the triggering
factor exacerbating sarcopenia development, as previously
suggested.49,54 Although patients with controlled CD showed
an increase of irisin values compared to those with active CD,
they did not reach the values of control subjects, despite
normalization of cortisol levels and an improvement in BMI
and WC. The persistence of low levels of circulating irisin
may also be associated with persistence of sarcopenic obesity,
despite biochemical remission, as frequently found with many
of the comorbidities of CD.29,55
An association between irisin and PTH levels was also
found. A recent study documented an interesting interplay
between irisin and PTH. Irisin produces several effects on
bone mineral density (BMD), stimulating osteoblast activ-
ity with increase of the cortical bone.25,56,57 By contrast,
PTH seems to act in the opposite way, since in endocrine
diseases, such as primary hyperparathyroidism, the pro-
longed action of elevated pathological PTH blood levels
causes BMD reduction. A recent research investigated the
relationship between irisin and PTH both by “in vitro
experiments” and by clinical evaluation in a cohort of
patients with primary hyperparathyroidism.58 As a result,
the authors showed that the two hormones inhibit one
Figure 2 Independent variables associated with circulating irisin levels in patients with controlled CD at multivariate analysis.
Abbreviations: WC, waist circumference; UFC, urinary free cortisol; CRT, chair rising test; BF%, body fat percentage.
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another. High PTH levels reduce the secretion of irisin in
mouse muscle cells, while irisin treatment is able to reduce
the PTH receptor expression in osteoblasts, thus blocking
its action. Moreover, the same authors also found that in
patients with primary hyperparathyroidism, irisin levels
were reduced by up to one-third compared to controls.
Interestingly, in the current study, we did not find
a significant correlation between circulating irisin levels
and glucose homeostasis likely due to the inclusion in the
study of patients with diabetes, prediabetes and normal
glucose tolerance.
The present study has a number of limitations. The
sample size of the study was relatively small. Myopathy
was assessed based on clinical symptoms and CRT.
Handgrip strength and instrumental techniques such as
Computed Tomography (CT) and Magnetic Resonance
Tomography (MRT) were not performed. Although irisin
levels are altered in several endocrine disorders, control
subjects were chosen among subjects who had visited the
endocrinology department, so the groups were both
matched based on metabolic disorders.
In conclusion, circulating irisin levels tend to be lower in
patientswithCDbefore and after correction of hypercortisolism
compared to controls. Circulating irisin levels are associated
with the presence of visceral obesity and osteosarcopenia in
patients with CD, showing that irisin may be a molecular
messenger in the complex axis formed by bone, muscle and
adipose tissue. Therefore, irisin remains ametabolicmarker that
needs to be further investigated as a possible marker of diag-
nosis of osteosarcopenic obesity in patients with CD.
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